
FDA’s Warning Letters Send a Clear Signal: Unapproved Drugs Are in the Crosshairs
CDER’s Office of Unapproved Drugs and Labeling Compliance (“OFDL”) has taken the lead in addressing high-priority enforcement areas involving unapproved
Regulatory developments, healthcare compliance analysis, FDA updates, and thought leadership articles. For a complete list of archived posts, visit FDA Unfiltered.

CDER’s Office of Unapproved Drugs and Labeling Compliance (“OFDL”) has taken the lead in addressing high-priority enforcement areas involving unapproved

On September 28 of this year, the FDA’s Office of Prescription Drug Promotion (“OPDP”) issued an Untitled Letter to Evolus,

Assuming we solve the “alignment problem” and humanity is not turned into paperclips, artificial intelligence will, likely, take a central